Related Experiment Videos
Intraoperative sentinel lymph node mapping in patients with colon cancer
J C Paramo1, J Summerall, C Wilson
1Department of Surgery, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, FL 33140, USA. jcparamo@med411.com
American Journal of Surgery
|September 5, 2001
Summary
Sentinel lymph node (SLN) mapping is a feasible technique for colon cancer, identifying the SLN in 71% of patients. This method accurately predicts non-SLN status and can upstage 11% of tumors.
Area of Science:
- Surgical Oncology
- Cancer Diagnostics
- Lymphatic System Research
Background:
- Sentinel lymph node (SLN) mapping, established in breast cancer and melanoma, is being explored for colon cancer.
- Accurate staging is crucial for effective colon cancer treatment and management.
Purpose of the Study:
- To evaluate the feasibility and accuracy of intraoperative SLN mapping in patients with colon cancer.
- To determine the SLN identification rate and its predictive value for non-SLN metastasis.
Main Methods:
- Thirty-five colon cancer patients underwent intraoperative SLN mapping using isosulfan blue dye injection.
- SLNs were identified by blue highlighting, and all lymph nodes were examined with H&E and CAM 5.2 stains.
Main Results:
- SLN mapping successfully identified the sentinel lymph node in 71% of patients.
- A 0% false negative rate was observed, indicating SLN status accurately predicted non-SLN metastasis.
- Micrometastases, detected only by CAM 5.2 staining, led to upstaging in 11% of patients.
Conclusions:
- Intraoperative SLN mapping is a viable technique for colon cancer staging with a 71% identification rate.
- Negative SLNs reliably indicate the absence of metastasis in other lymph nodes.
- SLN mapping with enhanced staining (CAM 5.2) improves detection of micrometastases, potentially benefiting 11% of patients with adjuvant therapy decisions.